196 filings
Page 2 of 10
CORRESP
zrf5v 503ytmmy
2 Jan 24
Correspondence with SEC
12:00am
UPLOAD
0mrnyhikxvtcatp
27 Dec 23
Letter from SEC
12:00am
6-K
riifvrpmwo90l 1ubh
21 Dec 23
Theratechnologies Announces Renewal of Shelf Prospectus and Filing of Registration Statement
4:24pm
F-3
fvk90pc78
21 Dec 23
Shelf registration (foreign)
1:21pm
6-K
lk3of69kf rwnu
13 Dec 23
Theratechnologies Announces FDA Approval of Trogarzo® 90-Second Intravenous (IV) Push Loading Dose
2:41pm
6-K
xwqek51g
6 Nov 23
Material Change Report
1:17pm
6-K
j3ymxgip
6 Nov 23
Investor Rights Agreement
12:28pm
6-K
3s5kt 5jv57l
3 Nov 23
First Amendment to Credit Agreement
2:26pm
6-K
ix1fr4syi0x8ezopj
31 Oct 23
Theratechnologies Announces Closing of US$25 Million Public Offering of
12:51pm
6-K
2umladcxippignjau
26 Oct 23
Current report (foreign)
9:15pm
SUPPL
gq27qs dncpfh
26 Oct 23
Supplemental materials (foreign)
9:13pm
6-K
p0ktzs401fm
26 Oct 23
Theratechnologies Announces Pricing of US$25 Million Public Offering of Common Shares and Concurrent Private Placement
9:50am
SUPPL
ie84fnb
25 Oct 23
Supplemental materials (foreign)
6:56pm
F-X
pp0lotxfgvqrmiodc ug
25 Oct 23
Appointment of agent for service of process by issuers registering securities
6:52pm
6-K
rbxb5s4racq76gb30zp
25 Oct 23
Theratechnologies Announces Proposed Public Offering of Common Shares and Concurrent Private Placement
5:31pm
6-K
a8g87i
24 Oct 23
Material Change Report
2:46pm
6-K
khpjq0xn
24 Oct 23
Theratechnologies Announces Operational Update
8:24am
6-K
a9ftgl
16 Oct 23
Theratechnologies Announces Finalization of Amendments to Some of the Terms and Conditions of its Credit Agreement with Marathon
3:04pm
6-K
4enqfy
26 Sep 23
Theratechnologies Reports Financial Results for the Third Quarter and Nine Months of Fiscal 2023 and Provides Business Updates
8:02am
6-K
92r8w7ikbt0hwjzb0kl
26 Sep 23
Interim Consolidated Financial Statements
8:00am